Sutro Biopharma (STU:S090) Research & Development: €130.09 Mil (TTM As of Mar. 2026)


STU:S090 Sutro Biopharma Inc STU:S090
45 GF Score
Price €6.24
GF Value €2.66
! 4 Warning Signs
View Full Analysis

What is Sutro Biopharma Research & Development?

Sutro Biopharma STU:S090 45 Research & Development is €130.09 Mil as of Mar. 2026. GuruFocus rates STU:S090 with a GF Score™ of 45/100 and a GF Value™ of €2.66. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sutro Biopharma's Research & Development for the three months ended in Mar. 2026 was €31.62 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €130.09 Mil.

Sutro Biopharma  (STU:S090) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sutro Biopharma Research & Development Related Terms

Sutro Biopharma Research & Development Historical Data

* Premium members only.

The historical data trend for Sutro Biopharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sutro Biopharma Research & Development Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.39 129.49 165.45 240.70 142.12

Sutro Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.73 33.23 33.96 31.29 31.62
STU:S090
45GF Score
Sutro Biopharma Inc STU:S090
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sutro Biopharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €130.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €130.09 Mil mean?
Sutro Biopharma (STU:S090) has a Research & Development of €130.09 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sutro Biopharma and its competitors.
Is Sutro Biopharma's Research & Development too high?
Sutro Biopharma's current Research & Development is €130.09 Mil. Overall, Sutro Biopharma has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Research & Development compare to CCCC and OCGN?
Sutro Biopharma's Research & Development of €130.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sutro Biopharma and its competitors. Sutro Biopharma's current Research & Development is €130.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Sutro Biopharma (STU:S090) has a current Research & Development of €130.09 Mil. The stock's GF Value™ is €2.66, compared to a current price of €6.24 — trading 134.4% above its estimated fair value. The current Research & Development is €130.09 Mil. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sutro Biopharma (STU:S090), the current Research & Development is €130.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sutro Biopharma (STU:S090) Overvalued in 2026?

Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued. The current stock price of €6.24 is trading 134.4% above its estimated GF Value™ of €2.66.

Key valuation signals for STU:S090:

  • Research & Development: €130.09 Mil
  • GF Value™: €2.66 vs. price of €6.24 (134.4% above fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the STU:S090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sutro Biopharma Business Description

Other Exchanges STRO:USAS090:Germany
Address 111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score

Get the complete analysis for STU:S090

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.24
Price
€2.66
GF Value